Evidence map›Paper›PMID 33594597›Full record

ArticleCanadian journal of anaesthesia = Journal canadien d'anesthesie2021

Variation in prophylactic tranexamic acid administration among anesthesiologists and surgeons in orthopedic surgery: a retrospective cohort study.

Brett L Houston, Dean A Fergusson, Jamie Falk, Robert Ariano, Donald S Houston, Emily Krupka, Anna Blankstein, Iris Perelman, Rodney H Breau, Daniel I McIsaac and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Brett L HoustonDepartment of Medical Oncology and Haematology, CancerCare Manitoba and Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada. bhouston@cancercare.mb.ca.ORCID http://orcid.org/0000-0002-8776-4083
Dean A FergussonClinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada.
Jamie FalkCollege of Pharmacy, University of Manitoba, Winnipeg, MB, Canada.
Robert ArianoCollege of Pharmacy, University of Manitoba, Winnipeg, MB, Canada.
Donald S HoustonDepartment of Medical Oncology and Haematology, CancerCare Manitoba and Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.
Emily KrupkaFaculty of Science, University of Manitoba, Winnipeg, MB, Canada.
Anna BlanksteinMax Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
Iris PerelmanClinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada.
Rodney H BreauClinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada.
Daniel I McIsaacClinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada.
Emily RimmerDepartment of Medical Oncology and Haematology, CancerCare Manitoba and Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.
Allan GarlandDepartments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Alan TinmouthClinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada.
Robert BalshawGeorge & Fay Yee Center for Healthcare Innovation, University of Manitoba/Winnipeg Regional Health Authority, Winnipeg, MB, Canada.
Alexis F TurgeonDepartment of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Faculty of Medicine, Université Laval, Québec City, QC, Canada.
Eric JacobsohnDepartment of Anesthesiology, Perioperative and Pain Medicine, University of Manitoba, Winnipeg, MB, Canada.
Eric BohmGeorge & Fay Yee Center for Healthcare Innovation, University of Manitoba/Winnipeg Regional Health Authority, Winnipeg, MB, Canada.
Ryan ZarychanskiDepartment of Medical Oncology and Haematology, CancerCare Manitoba and Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.
University of Manitoba · CACancerCare Manitoba · CAUniversity of Ottawa · CAWinnipeg Regional Health Authority · CAOttawa Hospital · CAUniversité Laval · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTranexamic acid (TXA) reduces red blood cell transfusion in various orthopedic surgeries, yet the degree of practice variation in its use among anesthesiologists and surgeons has not been described. To target future knowledge transfer and implementation strategies, and to better understand determinants of variability in prophylactic TXA use, our primary objective was to evaluate the influence of surgical team members on the variability of prophylactic TXA administration.

methodsThis was a retrospective cohort study of all adult patients undergoing primary total hip arthroplasty (THA), hip fracture surgery, and spine fusion ± vertebrectomy at two Canadian hospitals between January 2014 and December 2016. We used Canadian Classification of Health Interventions procedure codes within the Discharge Abstract Database which we linked to the Ottawa Data Warehouse. We described the percentage of patients that received TXA by individual surgery, the specifics of TXA dosing, and estimated the effect of anesthesiologists and surgeons on prophylactic TXA using multivariable mixed-effects logistic regression analyses.

resultsIn the 3,900 patients studied, TXA was most commonly used in primary THA (85%; n = 1,344/1,582), with lower use in hip fracture (23%; n = 342/1,506) and spine fusion surgery (23%; n = 186/812). The median [interquartile range] total TXA dose was 1,000 [1,000-1,000] mg, given as a bolus in 92% of cases. Anesthesiologists and surgeons added significant variability to the odds of receiving TXA in hip fracture surgery and spine fusion, but not primary THA. Most of the variability in TXA use was attributed to patient and other factors.

conclusionWe confirmed the routine use of TXA in primary THA, while observing lower utilization with more variability in hip fracture and spine fusion surgery. Further study is warranted to understand variations in use and the barriers to TXA implementation in a broader population of orthopedic surgical patients at high risk for transfusion.

Indexed as

Antifibrinolytic AgentsArthroplasty, Replacement, HipSurgeonsTranexamic AcidAdultAnesthesiologistsBlood Loss, SurgicalCanadaHumansRetrospective StudiesAntifibrinolytic AgentsTranexamic Acidblood conservationorthopedic surgeryretrospective cohort studytranexamic acid

Identifiers

PMID33594597
OpenAlexW3131421458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.